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Introduction
PAPA syndrome (pyogenic arthritis, pyoderma gangre-
nosum and acne syndrome) is a rare autoinflammatory
disease caused by mutations in the PSTPIP1 gene. This
disease is difficult to treat, but the combination of pre-
dnisone, an IL-1 inhibitor and a TNF-inhibitor has, in
our experience, helped even the most severely affected
patients. Treatment with anakinra appears to prevent
most of the severe joint manifestations, and treatment
with a TNF-inhibitor is most effective for treating and
preventing the pyoderma gangrenosum lesions.
Objectives
We report our observations on the treatment of 4
severely affected PAPA syndrome patients with exten-
sive pyoderma gangrenosum lesions.
Patients and methods
Medical records from 4 patients with PAPA syndrome
and severe pyoderma gangrenosum skin lesions were
reviewed. Three of these patients had remained at our
institution for extended visits while different therapeutic
regimens were tried. Photos of lesions were taken peri-
odically. CRP and ESR were followed.
Results
One patient, an 8 year old girl with extensive lesions on
her extremities requiring sedation for dressing changes,
had been treated with adalimumab, 20 mg every 14 days,
and pulses of methylprednisolone without effect. She
showed some improvement after being treated with inflixi-
mab. However, she developed generalized urticaria after
the second infusion. Despite etanercept, 2 mg/kg/week,
and frequent infusions of methylprednisolone, she wor-
sened and did not improve until she was started on
golimumab, 50 mg every 10 days. She eventually healed
completely.
A second teenage patient had extensive pyoderma gang-
renosum lesions, severe acne, and elevated inflammatory
markers. Etanercept was stopped when he developed ele-
vated transaminases. Adalimumab, 40 mg every week, led
to a minimal improvement. Infliximab caused an anaphy-
lactic reaction on the second infusion. Golimumab,
100 mg every 7 to 14 days, and a course of isotretinoin led
to the greatest improvement in this patient.
Two other patients with difficult-to-treat PAPA disease
improved, one on golimumab after an anaphylactic reac-
tion to infliximab and the other on high doses of inflixi-
mab. Both had shown minimal improvement on
etanercept and adalimumab.
Conclusion
Our observations indicate that treatment with infliximab,
if tolerated, or high dose golimumab may be more effec-
tive than high doses of etanercept or adalimumab in those
patients with PAPA syndrome and severe pyoderma gang-
renosum lesions.
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